253 related articles for article (PubMed ID: 21677600)
1. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
[TBL] [Abstract][Full Text] [Related]
2. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
[TBL] [Abstract][Full Text] [Related]
4. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
Watanabe T; Seguchi O; Nishimura K; Fujita T; Murata Y; Yanase M; Sato T; Sunami H; Nakajima S; Hisamatsu E; Sato T; Kuroda K; Hieda M; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
Int J Cardiol; 2016 Jan; 203():307-14. PubMed ID: 26523360
[TBL] [Abstract][Full Text] [Related]
5. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
6. Everolimus for cardiac allograft vasculopathy--every patient, at any time?
Patel JK; Kobashigawa JA
Transplantation; 2011 Jul; 92(2):127-8. PubMed ID: 21555972
[No Abstract] [Full Text] [Related]
7. Cardiac allograft vasculopathy compared by intravascular ultrasound sonography: everolimus to mycophenolate mofetil--one single-center experience.
Chou NK; Jan CF; Chi NH; Lee CM; Wu IH; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Chu SH; Wang SS
Transplant Proc; 2012 May; 44(4):897-9. PubMed ID: 22564578
[TBL] [Abstract][Full Text] [Related]
8. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
Valantine H
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
[TBL] [Abstract][Full Text] [Related]
11. Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial.
Arora S; Erikstad I; Ueland T; Sigurdardottir V; Ekmehag B; Jansson K; Eiskjaer H; Bøtker HE; Mortensen SA; Saunamaki K; Gude E; Ragnarsson A; Solbu D; Aukrust P; Gullestad L
Am J Transplant; 2012 Oct; 12(10):2700-9. PubMed ID: 22958738
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
13. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
Eisen H
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
[TBL] [Abstract][Full Text] [Related]
14. Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.
Rosing K; Fobker M; Kannenberg F; Gunia S; Dell'Aquila AM; Kwiecien R; Stypmann J; Nofer JR
Atherosclerosis; 2013 Sep; 230(1):164-70. PubMed ID: 23958269
[TBL] [Abstract][Full Text] [Related]
15. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
17. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
[TBL] [Abstract][Full Text] [Related]
18. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil.
Kaczmarek I; Ertl B; Schmauss D; Sadoni S; Knez A; Daebritz S; Meiser B; Reichart B
J Heart Lung Transplant; 2006 May; 25(5):550-6. PubMed ID: 16678034
[TBL] [Abstract][Full Text] [Related]
19. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
20. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
